Ultra Low–Dose Rituximab as Add-On Therapy in Anti-MDA5–Positive Patients With Polymyositis/Dermatomyositis–Associated ILD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Respiratory Medicine